With the development of transfection technology and the growing ease of transfection methods, it is very necessary to select a suitable transfection reagent to achieve the optimum transfection efficiency. Transfected cell types and delivered payload should be considered when selecting suitable transfection reagents.
Primary cells are generally more difficult to transfect than cell lines, so transfection reagents are required to facilitate the transfection of payloads into hard-to-transfect cells. The efficiency of our transfection reagents was assessed by using plasmid DNA (pDNA), short interfering RNA (siRNA), messenger RNA (mRNA), and ribonucleoprotein (RNP). These tables below summarize optimal transfection reagents for nucleic acids or proteins in different cell types.
Primary cells are isolated or harvested directly from living tissue or organs. The morphological and physiological characteristics of primary cells are similar to those of the tissue of origin. However, primary cells have a finite lifespan and limited expansion capacity and are usually more difficult to transfect than cell lines. Transfection of primary mammalian cells is an essential tool for scientific and therapeutical applications, such as functional genomics, drug development, and gene-based medicine.
|Umbilical Cord Blood Derived Mesenchymal Stem Cells (UCB-MSC)||pDNA||pDNA||pDNA|
|Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC)||pDNA||pDNA||pDNA|
|Vascular smooth muscle Cells (VSMCs)||pDNA||pDNA|
|Human Umbilical Vein Endothelial Cells (HUVECs)||pDNA|
|Mononuclear Cells from CML patients (MNC)||pDNA||siRNA||siRNA|
|Human Foreskin Fibroblast Cells||pDNA|
|Rat Primary Sympathetic Neurons||pDNA||mRNA|
Cell lines derived from primary cultures can be propagated repeatedly and sometimes indefinitely. When they are passed on, the cells with the highest growth capacity dominate, resulting in a degree of genotype and phenotypic consistency in the population.
Although cell lines are artificial model systems that do not necessarily reflect the biochemical status of the primary cells, they are primarily used in transfection studies because they are readily available and are generally easier to transfect.
|Kidney Fibroblast Cells (293-T)||pDNA||pDNA||pDNA|
|Breast Cancer Cells (MDA-MB-231)||pDNA||pDNA||pDNA||siRNA||mRNA|
|Kidney Epithelial Cells (MDCK)||siRNA|
|Breast Cancer/Melanoma Cells (MDA-MB-436)||pDNA||siRNA||mRNA||RNP|
|Breast Cancer Cells (MDA-MB-468)||siRNA|
|Breast Cancer Cells (Sum-149PT)||pDNA||siRNA|
|Breast Cancer Cells (MCF-7)||pDNA||pDNA||pDNA||mRNA|
|Human Lymphoma Cells (U-937)||pDNA||pDNA|
|Chronic Myeloid Leukaemia Cells (K562)||siRNA||pDNA||siRNA||mRNA|
|Acute Myeloid Leukemia Cells (KG1 and KG1A)||siRNA||siRNA|
|Acute Myeloid Leukemia Cells (THP1)||siRNA||siRNA||mRNA|
|Human Lung Cancer Cells (A549)||siRNA|
|Human Colon Cancer (HCT-116)||siRNA||siRNA|
An ideal reagent should have low cytotoxicity and high transfection efficiency for the required cell types. The reagent levels and the cytotoxicity parameters should be considered before selecting an appropriate transfection reagent. Amerigo Scientific offers products that have significant transfection advantages over the main products on the market.
|Product Name||High Transfection Efficiency||Simple Protocol||Toxicity|
|All-Fect||Provides 2 to 3-fold higher efficacy in the presences of serum||No need to change tissue culture medium during transfection||Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology|
|Prime-Fect||Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology|
|Leu-Fect-A / Leu-Fect-B||Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology|
|Trans-Booster||Provides 2 to 3-fold higher efficacy in the presences of usual transfection reagent||No need to change tissue culture medium during transfection||Less toxic compared to lipofection and polymeric reagents, leading to better protein yields from the transfected cells|
|mRNA-Fect||Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents||No need to change tissue culture medium during transfection|
|CRISP-Fect||Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents||No need to change tissue culture medium during transfection||Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology|
|In Vivo DNA-Fect||Provides 2 to 3-fold higher efficacy under serum conditions||Can be administered with simple formulations such as saline||Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells|
|In Vivo RNA-Fect||Provides effective transfection under physiological conditions||siRNA particles can be prepared in saline suitable for administration|